Colorcon Launches New Technical Center in Australia
The new facility will give the company’s Australian customers access to tablet formulation and coating services in order to shorten supply chains and increase the region’s pharmaceutical sector capacity.
Colorcon, a film coating systems and excipients development company headquartered in Harleysville, PA, announced on August 5, 2020 that it has opened a new technical center in Melbourne, Australia.
The new facility will give the company’s Australian customers access to tablet formulation and coating services in order to shorten supply chains and increase the region’s pharmaceutical sector capacity, a company press release said.
“The new technical service center will provide both large and small customers the opportunity to work directly with Colorcon and for the first time in Australia to conduct laboratory-scale compression and coating trials, using automated coating equipment, saving valuable development time and cost,” said Tim Horwood, business development manager, Colorcon, in the press release.
“Opening this facility demonstrates Colorcon’s continued commitment to supporting the growing pharmaceutical and nutritional markets in Australia, reducing our customer’s time to market during product development,” added David Wei, general manager, Colorcon South East Asia, in the press release. “The investment reflects Colorcon’s dedication to providing best-in-class products and services.”
Source: Colorcon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
